Long-Term Outcomes of HIPEC for Appendiceal Cancer
Author Information
Author(s): Levine Edward A. MD, Cos Heidy MD, Votanopoulos Konstantinos I. MD, PhD, Shen Perry MD, Russell Greg MS, Mansfield Paul MD, Fournier Keith MD, Bartlett David MD, Stewart John H. MD, MBA
Primary Institution: Wake Forest Baptist Health
Hypothesis
Does the use of mitomycin C or oxaliplatin in HIPEC provide better long-term survival outcomes for patients with appendiceal neoplasms?
Conclusion
Both oxaliplatin and mitomycin C have similar long-term efficacy for HIPEC in patients with appendiceal neoplasms and peritoneal dissemination.
Supporting Evidence
- The 10-year survival rate was 56.2% with mitomycin C and 47.5% with oxaliplatin.
- The average peritoneal cancer index scores were similar between the two groups.
- Long-term survival is possible even for high-grade disease if complete cytoreduction is achieved.
Takeaway
This study shows that patients with appendiceal cancer can live a long time after surgery and special chemotherapy, no matter which type of medicine they get.
Methodology
Patients with mucinous appendiceal neoplasms and peritoneal dissemination were enrolled in a randomized trial comparing HIPEC with oxaliplatin or mitomycin C, with survival rates calculated at 10 years.
Limitations
The study was not powered sufficiently to define small differences in survival, and results may vary at less experienced centers.
Participant Demographics
57% female, mean age 55.3 years, 92% Caucasian.
Statistical Information
P-Value
p=0.83
Statistical Significance
p=0.83
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website